Machine learning models for drug-drug interaction prediction from computational discovery to clinical application

Drug-drug interaction (DDI) poses a major challenge in clinical pharmacology, often compromising therapeutic efficacy or causing serious adverse events. Traditional detection methods, heavily dependent on experimental assays and expert knowledge, are constrained by high costs and limited scalability. This work explores emerging machine learning (ML)-based strategies for predicting DDIs by leveraging the rapidly expanding biomedical data landscape. Recent advances in deep learning architectures, graph neural networks and sophisticated feature engineering have markedly improved predictive performance, offering scalable and data-efficient alternatives to conventional approaches. We further highlight real-world clinical applications where ML-based models have enhanced drug safety monitoring and informed therapeutic decision-making. Finally, we discuss critical challenges like model interpretability, generalizability and integration with clinical workflows, and outline future directions toward building robust, explainable and clinically actionable DDI prediction systems. This work provides a comprehensive perspective on how AI-driven methodologies are reshaping pharmacovigilance and precision therapeutics.

Authors

Institutions

Publication Details

Journal
npj Digital Medicine
Published
2026-01-29
DOI
https://doi.org/10.1038/s41746-026-02400-3
Citations
1
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
33.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Machine learning models for drug-drug interaction prediction from computational discovery to clinical application

Yinfeng Yang, Jinghui Wang, Yuqing Lu, Haiyang Sheng et al.
1 citations
npj Digital Medicine
Pharmacovigilance and Adverse Drug Reactions
33.63
article

Machine learning models for drug-drug interaction prediction from computational discovery to clinical application

Yinfeng Yang, Jinghui Wang, Yuqing Lu, Haiyang Sheng, Wenchao Song, Nini Fan, Jing Chen
article en
1 citations

Abstract

Drug-drug interaction (DDI) poses a major challenge in clinical pharmacology, often compromising therapeutic efficacy or causing serious adverse events. Traditional detection methods, heavily dependent on experimental assays and expert knowledge, are constrained by high costs and limited scalability. This work explores emerging machine learning (ML)-based strategies for predicting DDIs by leveraging the rapidly expanding biomedical data landscape. Recent advances in deep learning architectures, graph neural networks and sophisticated feature engineering have markedly improved predictive performance, offering scalable and data-efficient alternatives to conventional approaches. We further highlight real-world clinical applications where ML-based models have enhanced drug safety monitoring and informed therapeutic decision-making. Finally, we discuss critical challenges like model interpretability, generalizability and integration with clinical workflows, and outline future directions toward building robust, explainable and clinically actionable DDI prediction systems. This work provides a comprehensive perspective on how AI-driven methodologies are reshaping pharmacovigilance and precision therapeutics.

npj Digital MedicineVol. 9(1)
Anhui Medical University (CN), Anhui University of Traditional Chinese Medicine (CN), Bristol-Myers Squibb (United States) (US)
Openalex Percentile: Top 2%
Pharmacovigilance and Adverse Drug Reactions
33.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.